ReSync Bio is Joining Benchling

Today, I’m excited to share that the ReSync Bio team has been acquired by Benchling.

Throughout ReSync's journey, the vision has remained clear: accelerate drug discovery teams across the industry. We gave scientists no‑code access to advanced AI tools without the need to build their own infrastructure. This ecosystem was built in a multitude of ways: through industry partnerships with NVIDIA BioNeMo, open-source tools including Boltz and REINVENT4, and incredible commercial partners like Rowan. These tools helped teams move faster from idea to insight, and from digital to experimental. I am extremely proud of and thankful to our tight-knit team that accomplished quickly what takes others years or decades. 

Joining Benchling is the next chapter in scaling that mission. Benchling serves hundreds of thousands of scientists and offers the reach and platform infrastructure for our work to accelerate impactful workflows across the industry. We’re excited to bring ReSync’s vision and mission to Benchling’s scale.

Over the coming months, we’ll be sunsetting the ReSync platform and working directly with customers to support a smooth transition.

You can read more in the official announcement from Benchling here - keep an eye on the Benchling blog for more on their AI roadmap.

Thank you to everyone who supported ReSync and believed in our mission. This journey has inspired us, and we're even more excited for what we’ll create next as part of Benchling.

Mihir, Nishanth, Lindsay, Tony, and Chelsea